p-hydroxymethylphenyl 2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside | 78617-46-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-hydroxymethylphenyl 2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside
• 英文别名: [(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate
• CAS: 78617-46-6
• 化学式: C₂₁H₂₆O₁₁
• 分子量: 454.431
• InChiKey: HGUDVDQXCUHOED-ADAARDCZSA-N

物化性质

• 沸点：
  551.4±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  β-D-葡萄糖五乙酸酯 以58%的产率得到
  参考文献：
  名称：

  KIROMURA, KEISUKE;KITAZAWA, SADAYA;TAKATA, YASUSHI;SAKAKIBARA, TOSHIYUKI

  摘要：

  DOI：

文献信息

• Effector conjugates, methods for their preparation and their pharmaceutical use
  申请人：——

  公开号：US20040167083A1

  公开（公告）日：2004-08-26

  Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

  描述了具有适当的糖或糖衍生物（作为识别单元）的紫杉醇和紫杉醇衍生物（作为效应物）的共轭物。它们的制备是通过将识别单元与适当的连接剂反应，然后将产生的化合物与效应物共轭。描述了共轭物在治疗增殖或血管生成相关过程方面的药物应用。
• Glycosidation catalyst and process for preparing glycoside derivatives
  申请人：NIPPON FINE CHEMICAL CO., LTD.

  公开号：EP0263027A1

  公开（公告）日：1988-04-06

  Disclosed are a glycosidation catalyst comprising at least one of heteropoly acids represented by the formula H aX pM qO r·bH₂O wherein X is P, As, Si or Ge, M is at least one species selected from the group consisting of Mo, W and V, a is 3 4 or 6, b is an integer of 0 to 30, p is 1 or 2, q is 12 or 18, and r is 40 or 62, with the proviso that when X is P or As, a is 3 or 6; when X is Si or Ge, a is 4; and further (1) when X is P or As and a is 3, or when X is Si or Ge and a is 4, M is at least one species selected from the group consisting of Mo, W and V, p is 1, q is 12 and r is 40; and (2) when X is P or As and a is 6, M is Mo or W, p is 2, q is 18 and r is 62, and a process for preparing a glycoside derivative by using said catalyst.

  本发明公开了一种糖苷催化剂，它包含至少一种由式 H aX pM qO r-bH₂O 表示的杂多酸。 H aX pM qO r-bH₂O 其中 X 是 P、As、Si 或 Ge，M 是至少一种选自 Mo、W 和 V 组成的组的物质，a 是 3 4 或 6，b 是 0 至 30 的整数，p 是 1 或 2，q 是 12 或 18，r 是 40 或 62，但条件是当 X 是 P 或 As 时，a 是 3 或 6；当 X 是 Si 或 Ge 时，a 是 4；以及 (1) 当 X 为 P 或 As 且 a 为 3，或当 X 为 Si 或 Ge 且 a 为 4 时，M 为至少一种选自 Mo、W 和 V 组成的组的物质，p 为 1，q 为 12，r 为 40；以及 (2) 当 X 为 P 或 As 且 a 为 6 时，M 为 Mo 或 W，p 为 2，q 为 18，r 为 62，以及使用所述催化剂制备苷衍生物的工艺。
• Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2009114A1

  公开（公告）日：2008-12-31

  The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention further relates to methods, compounds and uses of said compounds for treating subjects suffering from said pathologic disorder, optionally in combination with other therapeutic agents. Also provided are genes and/or proteins encoded by them whose expression level have been determined to differ between epothilone responders and epothilone non-responders.

  本发明提供了通过分析从所述受试者处获得的样本中的基因表达谱和/或某些分子标记物来确定患有病理紊乱（包括非小细胞肺癌（NSCLC））的受试者对表霉素治疗的潜在反应性的方法、试剂盒和化合物。本发明还涉及用于治疗所述病理紊乱的受试者的方法、化合物和用途，可选择与其他治疗剂联合使用。本发明还提供了基因和/或由其编码的蛋白质，这些基因和/或蛋白质的表达水平已被确定在埃博霉素应答者和埃博霉素非应答者之间存在差异。
• Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
  申请人：LABORATOIRES HOECHST S.A.

  公开号：EP0511917B1

  公开（公告）日：1996-10-23
• US4874852A
  申请人：——

  公开号：US4874852A

  公开（公告）日：1989-10-17